Good price  online

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Hepatobiliary Cancer Cirrhosis Hepatitis C Drugs
Created with Pixso. Lenvatinib Mesilate Capsules 10mg 30 Capsules Box Advanced Hepatocellular Carcinoma First Line Multi Kinase VEGFR FGFR TKI

Lenvatinib Mesilate Capsules 10mg 30 Capsules Box Advanced Hepatocellular Carcinoma First Line Multi Kinase VEGFR FGFR TKI

Brand Name: Sichuan Kelun Pharmaceutical Co., Ltd.
Model Number: Lenvatinib KL-20237178
MOQ: Negotiable
Price: Please contact a specialist WhatsApp:55342706
Delivery Time: Negotiable
Payment Terms: Western Union,MoneyGram,T/T
Detail Information
Place of Origin:
Chengdu, Sichuan, China
Certification:
NMPA/GMP
Packaging Details:
Negotiable
Supply Ability:
Negotiable
Highlight:

HCC First Line Oral TKI

,

VEGFR FGFR RET PDGFR Inhibitor

,

Advanced Liver Cancer Capsule

Product Description

Lenvatinib Mesilate 10mg x 30 Capsules

[Product Name]

Generic Name: Lenvatinib Mesilate

Specification: 10mg x 30 Capsules

[Active Ingredient]

Lenvatinib Mesilate

[Indications]

First-line unresectable hepatocellular carcinoma. Also for DTC and RCC. Weight-based HCC dosing >=60kg: 12mg/day; <60kg: 8mg/day.

[Mechanism of Action]

Potent multi-targeted TKI (VEGFR1-3, FGFR1-4, PDGFRa, c-KIT, RET). Broad anti-angiogenic and antiproliferative activity.

[Dosage and Administration]

HCC: 8-12mg based on body weight. RCC: 18mg with everolimus. Take consistently with or without food.

[Adverse Reactions]

Hypertension, fatigue, diarrhea, proteinuria, hand-foot syndrome, hypothyroidism. Hypertensive crisis, cardiac dysfunction, hepatotoxicity.

[Storage]

Store below 30C. Keep out of reach of children.

[Shelf Life]

24 months

Approval: H20237178